Redeye has updated its estimates for Carasent following the Q4 2023 report, which showed slightly stronger sales but somewhat lower margins. Although organic recurring revenues only grew by a mere 13%, there are indications of underlying improvements. Q4 2023 marked a record quarter in terms of new sales, and several product launches in 2024 could potentially boost Carasent's growth numbers. Going forward, improved sales volumes and flattish costs will be the name of the game.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Carasent - Steps taken towards stronger growth

© Modular Finance, source Nordic Press Releases